Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 19, 2025 (Event Date)
Reporting Period: Specific event regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Nasdaq Listing Status: The Company previously received notice of noncompliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock failing to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days. On February 19, 2025, the Company received formal notice from Nasdaq confirming it has regained compliance with the minimum bid price requirement. Consequently, the Company's common stock will continue to be listed and traded on The Nasdaq Stock Market LLC.
Guidance, Outlook, and Risks
Future Compliance Risk: Under Listing Rule 5815(d)(4)(B), the Company will not be eligible for the customary 180-day grace period if the bid price falls below $1.00 for 30 consecutive trading days again. In such an event, the Company would receive a delisting letter, though it would retain the right to request a hearing for an exception.
Management Commentary: The filing references a press release dated February 24, 2025, titled "Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval," which is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the current trading price of REVB to ensure it remains above the $1.00 minimum bid price threshold.
- Review the attached press release (Exhibit 99.1) for any additional details on the compliance timeline.
- Monitor future 8-K filings for any new notices regarding bid price noncompliance, noting the loss of the 180-day grace period.
- Check the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.